VERTEX PHARMACEUTICALS INC / MA Finance Lease, Liability, Noncurrent
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Finance Lease, Liability, Noncurrent of $106.70 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:FinanceLeaseLiabilityNoncurrent · last filed 2026-02-13
- 2025-12-31: Finance Lease, Liability, Noncurrent $106.70M.
- 2025-03-31: Finance Lease, Liability, Noncurrent $111.40M.
- 2024-12-31: Finance Lease, Liability, Noncurrent $112.80M.
- 2024-09-30: Finance Lease, Liability, Noncurrent $114.00M.
| Period end | Finance Lease, Liability, Noncurrent | Finance Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2025-12-31 | $106.70M 10-K · filed 2026-02-13 | |
| 2025-03-31 | $111.40M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $112.80M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $114.00M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $346.60M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $361.50M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $376.10M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $390.30M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $404.10M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $417.60M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $430.80M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $442.30M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $482.30M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $495.50M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $509.80M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $513.25M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $524.92M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $530.33M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $539.00M 10-K · filed 2022-02-09 | $539.04M 10-K · filed 2021-02-11 |
| 2020-09-30 | $546.51M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $522.07M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $532.95M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $538.58M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $541.56M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $551.53M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $560.38M 10-Q · filed 2019-05-01 | |
| 2019-01-01 | $569.49M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |